 | • レポートコード：D005-00475 • 出版社/出版日：GlobalInfoResearch / 2020年5月29日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、129ページ • 納品方法：Eメール • 産業分類：医療・製薬 |
| Single User | ￥522,000 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥783,000 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,044,000 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、血液がんの世界市場を広く調査・分析し、今後の市場展望をまとめております。血液がんの種類別市場規模（薬理療法、幹細胞移植、外科＆放射線療法、貧血治療、血栓症治療、好中球減少症治療、対症療法）、用途別市場規模（流行病、白血病幹細胞病態生理、腎臓病、遺伝病、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Karyopharm Therapeutics、Abbott Laboratories、AbbVie、Johnson & Johnson、Celgene Corporation、Roche Diagnostics A/S、HemoCue AB、Kite Pharma、Novartis、Beckman Coulter、Bio-Rad Laboratories、Horiba、C. R. Bard、Astellas Pharma US、The Medicine Company、Mindray Medical International Limited、Siemens AG、DiagnoCure Inc.、Pharmacyclics、Sysmex ・地域別グローバル市場分析 2015年-2020年 ・血液がんの北米市場（アメリカ、カナダ、メキシコ） ・血液がんのヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・血液がんのアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・血液がんの南米市場（ブラジル、アルゼンチン） ・血液がんの中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：薬理療法、幹細胞移植、外科＆放射線療法、貧血治療、血栓症治療、好中球減少症治療、対症療法 ・用途別分析：流行病、白血病幹細胞病態生理、腎臓病、遺伝病、その他 ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論 |
Market Overview
The global Hematological Cancers market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
The Hematological Cancers market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Hematological Cancers market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Hematological Cancers market has been segmented into:
Pharmacological Therapies
Stem Cell Transplantation
Surgery and Radiation Therapy
Anemia Treatment
Thrombosis Treatment
Neutopenia Treatment
Symptomatic treatment
By Application, Hematological Cancers has been segmented into:
Epidemiology
Pathophysiology of Leukemic Stem Cells
Kidney Diseases
Genetic Diseases
Other Diseases
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Hematological Cancers market presented in the report. This section sheds light on the sales growth of different regional and country-level Hematological Cancers markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Hematological Cancers market.
The report offers in-depth assessment of the growth and other aspects of the Hematological Cancers market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Competitive Landscape and Hematological Cancers Market Share Analysis
Hematological Cancers competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Hematological Cancers sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Hematological Cancers sales, revenue and market share for each player covered in this report.
The major players covered in Hematological Cancers are:
Karyopharm Therapeutics
Abbott Laboratories
AbbVie
Johnson & Johnson
Celgene Corporation
Roche Diagnostics A/S
HemoCue AB
Kite Pharma
Novartis
Beckman Coulter
Bio-Rad Laboratories
Horiba
C. R. Bard
Astellas Pharma US
The Medicine Company
Mindray Medical International Limited
Siemens AG
DiagnoCure Inc.
Pharmacyclics
Sysmex
Table of Contents
1 Hematological Cancers Market Overview
1.1 Product Overview and Scope of Hematological Cancers
1.2 Classification of Hematological Cancers by Type
1.2.1 Global Hematological Cancers Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Hematological Cancers Revenue Market Share by Type in 2019
1.2.3 Pharmacological Therapies
1.2.4 Stem Cell Transplantation
1.2.5 Surgery and Radiation Therapy
1.2.6 Anemia Treatment
1.2.7 Thrombosis Treatment
1.2.8 Neutopenia Treatment
1.2.9 Symptomatic treatment
1.3 Global Hematological Cancers Market by Application
1.3.1 Overview: Global Hematological Cancers Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Epidemiology
1.3.3 Pathophysiology of Leukemic Stem Cells
1.3.4 Kidney Diseases
1.3.5 Genetic Diseases
1.3.6 Other Diseases
1.4 Global Hematological Cancers Market by Regions
1.4.1 Global Hematological Cancers Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Hematological Cancers (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Hematological Cancers Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Hematological Cancers Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Hematological Cancers Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Hematological Cancers Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Hematological Cancers Status and Prospect (2015-2025)
2 Company Profiles
2.1 Karyopharm Therapeutics
2.1.1 Karyopharm Therapeutics Details
2.1.2 Karyopharm Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Karyopharm Therapeutics SWOT Analysis
2.1.4 Karyopharm Therapeutics Product and Services
2.1.5 Karyopharm Therapeutics Hematological Cancers Revenue, Gross Margin and Market Share (2018-2019)
2.2 Abbott Laboratories
2.2.1 Abbott Laboratories Details
2.2.2 Abbott Laboratories Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Abbott Laboratories SWOT Analysis
2.2.4 Abbott Laboratories Product and Services
2.2.5 Abbott Laboratories Hematological Cancers Revenue, Gross Margin and Market Share (2018-2019)
2.3 AbbVie
2.3.1 AbbVie Details
2.3.2 AbbVie Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 AbbVie SWOT Analysis
2.3.4 AbbVie Product and Services
2.3.5 AbbVie Hematological Cancers Revenue, Gross Margin and Market Share (2018-2019)
2.4 Johnson & Johnson
2.4.1 Johnson & Johnson Details
2.4.2 Johnson & Johnson Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Johnson & Johnson SWOT Analysis
2.4.4 Johnson & Johnson Product and Services
2.4.5 Johnson & Johnson Hematological Cancers Revenue, Gross Margin and Market Share (2018-2019)
2.5 Celgene Corporation
2.5.1 Celgene Corporation Details
2.5.2 Celgene Corporation Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Celgene Corporation SWOT Analysis
2.5.4 Celgene Corporation Product and Services
2.5.5 Celgene Corporation Hematological Cancers Revenue, Gross Margin and Market Share (2018-2019)
2.6 Roche Diagnostics A/S
2.6.1 Roche Diagnostics A/S Details
2.6.2 Roche Diagnostics A/S Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Roche Diagnostics A/S SWOT Analysis
2.6.4 Roche Diagnostics A/S Product and Services
2.6.5 Roche Diagnostics A/S Hematological Cancers Revenue, Gross Margin and Market Share (2018-2019)
2.7 HemoCue AB
2.7.1 HemoCue AB Details
2.7.2 HemoCue AB Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 HemoCue AB SWOT Analysis
2.7.4 HemoCue AB Product and Services
2.7.5 HemoCue AB Hematological Cancers Revenue, Gross Margin and Market Share (2018-2019)
2.8 Kite Pharma
2.8.1 Kite Pharma Details
2.8.2 Kite Pharma Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Kite Pharma SWOT Analysis
2.8.4 Kite Pharma Product and Services
2.8.5 Kite Pharma Hematological Cancers Revenue, Gross Margin and Market Share (2018-2019)
2.9 Novartis
2.9.1 Novartis Details
2.9.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Novartis SWOT Analysis
2.9.4 Novartis Product and Services
2.9.5 Novartis Hematological Cancers Revenue, Gross Margin and Market Share (2018-2019)
2.10 Beckman Coulter
2.10.1 Beckman Coulter Details
2.10.2 Beckman Coulter Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Beckman Coulter SWOT Analysis
2.10.4 Beckman Coulter Product and Services
2.10.5 Beckman Coulter Hematological Cancers Revenue, Gross Margin and Market Share (2018-2019)
2.11 Bio-Rad Laboratories
2.11.1 Bio-Rad Laboratories Details
2.11.2 Bio-Rad Laboratories Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Bio-Rad Laboratories SWOT Analysis
2.11.4 Bio-Rad Laboratories Product and Services
2.11.5 Bio-Rad Laboratories Hematological Cancers Revenue, Gross Margin and Market Share (2018-2019)
2.12 Horiba
2.12.1 Horiba Details
2.12.2 Horiba Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 Horiba SWOT Analysis
2.12.4 Horiba Product and Services
2.12.5 Horiba Hematological Cancers Revenue, Gross Margin and Market Share (2018-2019)
2.13 C. R. Bard
2.13.1 C. R. Bard Details
2.13.2 C. R. Bard Major Business and Total Revenue (Financial Highlights) Analysis
2.13.3 C. R. Bard SWOT Analysis
2.13.4 C. R. Bard Product and Services
2.13.5 C. R. Bard Hematological Cancers Revenue, Gross Margin and Market Share (2018-2019)
2.14 Astellas Pharma US
2.14.1 Astellas Pharma US Details
2.14.2 Astellas Pharma US Major Business and Total Revenue (Financial Highlights) Analysis
2.14.3 Astellas Pharma US SWOT Analysis
2.14.4 Astellas Pharma US Product and Services
2.14.5 Astellas Pharma US Hematological Cancers Revenue, Gross Margin and Market Share (2018-2019)
2.15 The Medicine Company
2.15.1 The Medicine Company Details
2.15.2 The Medicine Company Major Business and Total Revenue (Financial Highlights) Analysis
2.15.3 The Medicine Company SWOT Analysis
2.15.4 The Medicine Company Product and Services
2.15.5 The Medicine Company Hematological Cancers Revenue, Gross Margin and Market Share (2018-2019)
2.16 Mindray Medical International Limited
2.16.1 Mindray Medical International Limited Details
2.16.2 Mindray Medical International Limited Major Business and Total Revenue (Financial Highlights) Analysis
2.16.3 Mindray Medical International Limited SWOT Analysis
2.16.4 Mindray Medical International Limited Product and Services
2.16.5 Mindray Medical International Limited Hematological Cancers Revenue, Gross Margin and Market Share (2018-2019)
2.17 Siemens AG
2.17.1 Siemens AG Details
2.17.2 Siemens AG Major Business and Total Revenue (Financial Highlights) Analysis
2.17.3 Siemens AG SWOT Analysis
2.17.4 Siemens AG Product and Services
2.17.5 Siemens AG Hematological Cancers Revenue, Gross Margin and Market Share (2018-2019)
2.18 DiagnoCure Inc.
2.18.1 DiagnoCure Inc. Details
2.18.2 DiagnoCure Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.18.3 DiagnoCure Inc. SWOT Analysis
2.18.4 DiagnoCure Inc. Product and Services
2.18.3 DiagnoCure Inc. Hematological Cancers Revenue, Gross Margin and Market Share (2018-2019)
2.19 Pharmacyclics
2.19.1 Pharmacyclics Details
2.19.2 Pharmacyclics Major Business and Total Revenue (Financial Highlights) Analysis
2.19.3 Pharmacyclics SWOT Analysis
2.19.4 Pharmacyclics Product and Services
2.19.5 Pharmacyclics Hematological Cancers Revenue, Gross Margin and Market Share (2018-2019)
2.20 Sysmex
2.20.1 Sysmex Details
2.20.2 Sysmex Major Business and Total Revenue (Financial Highlights) Analysis
2.20.3 Sysmex SWOT Analysis
2.20.4 Sysmex Product and Services
2.20.5 Sysmex Hematological Cancers Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Hematological Cancers Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Hematological Cancers Players Market Share
3.2.2 Top 10 Hematological Cancers Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Hematological Cancers Revenue and Market Share by Regions
4.2 North America Hematological Cancers Revenue and Growth Rate (2015-2020)
4.3 Europe Hematological Cancers Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Hematological Cancers Revenue and Growth Rate (2015-2020)
4.5 South America Hematological Cancers Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Hematological Cancers Revenue and Growth Rate (2015-2020)
5 North America Hematological Cancers Revenue by Countries
5.1 North America Hematological Cancers Revenue by Countries (2015-2020)
5.2 USA Hematological Cancers Revenue and Growth Rate (2015-2020)
5.3 Canada Hematological Cancers Revenue and Growth Rate (2015-2020)
5.4 Mexico Hematological Cancers Revenue and Growth Rate (2015-2020)
6 Europe Hematological Cancers Revenue by Countries
6.1 Europe Hematological Cancers Revenue by Countries (2015-2020)
6.2 Germany Hematological Cancers Revenue and Growth Rate (2015-2020)
6.3 UK Hematological Cancers Revenue and Growth Rate (2015-2020)
6.4 France Hematological Cancers Revenue and Growth Rate (2015-2020)
6.5 Russia Hematological Cancers Revenue and Growth Rate (2015-2020)
6.6 Italy Hematological Cancers Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Hematological Cancers Revenue by Countries
7.1 Asia-Pacific Hematological Cancers Revenue by Countries (2015-2020)
7.2 China Hematological Cancers Revenue and Growth Rate (2015-2020)
7.3 Japan Hematological Cancers Revenue and Growth Rate (2015-2020)
7.4 Korea Hematological Cancers Revenue and Growth Rate (2015-2020)
7.5 India Hematological Cancers Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Hematological Cancers Revenue and Growth Rate (2015-2020)
8 South America Hematological Cancers Revenue by Countries
8.1 South America Hematological Cancers Revenue by Countries (2015-2020)
8.2 Brazil Hematological Cancers Revenue and Growth Rate (2015-2020)
8.3 Argentina Hematological Cancers Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Hematological Cancers by Countries
9.1 Middle East & Africa Hematological Cancers Revenue by Countries (2015-2020)
9.2 Saudi Arabia Hematological Cancers Revenue and Growth Rate (2015-2020)
9.3 UAE Hematological Cancers Revenue and Growth Rate (2015-2020)
9.4 Egypt Hematological Cancers Revenue and Growth Rate (2015-2020)
9.5 South Africa Hematological Cancers Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Hematological Cancers Revenue and Market Share by Type (2015-2020)
10.2 Global Hematological Cancers Market Forecast by Type (2019-2024)
10.3 Pharmacological Therapies Revenue Growth Rate (2015-2025)
10.4 Stem Cell Transplantation Revenue Growth Rate (2015-2025)
10.5 Surgery and Radiation Therapy Revenue Growth Rate (2015-2025)
10.6 Anemia Treatment Revenue Growth Rate (2015-2025)
10.7 Thrombosis Treatment Revenue Growth Rate (2015-2025)
10.8 Neutopenia Treatment Revenue Growth Rate (2015-2025)
10.9 Symptomatic treatment Revenue Growth Rate (2015-2025)
11 Global Hematological Cancers Market Segment by Application
11.1 Global Hematological Cancers Revenue Market Share by Application (2015-2020)
11.2 Hematological Cancers Market Forecast by Application (2019-2024)
11.3 Epidemiology Revenue Growth (2015-2020)
11.4 Pathophysiology of Leukemic Stem Cells Revenue Growth (2015-2020)
11.5 Kidney Diseases Revenue Growth (2015-2020)
11.6 Genetic Diseases Revenue Growth (2015-2020)
11.7 Other Diseases Revenue Growth (2015-2020)
12 Global Hematological Cancers Market Size Forecast (2021-2025)
12.1 Global Hematological Cancers Market Size Forecast (2021-2025)
12.2 Global Hematological Cancers Market Forecast by Regions (2021-2025)
12.3 North America Hematological Cancers Revenue Market Forecast (2021-2025)
12.4 Europe Hematological Cancers Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Hematological Cancers Revenue Market Forecast (2021-2025)
12.6 South America Hematological Cancers Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Hematological Cancers Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US
Table 1. Global Hematological Cancers Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Hematological Cancers by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Hematological Cancers Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Hematological Cancers Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Karyopharm Therapeutics Corporate Information, Location and Competitors
Table 6. Karyopharm Therapeutics Hematological Cancers Major Business
Table 7. Karyopharm Therapeutics Hematological Cancers Total Revenue (USD Million) (2017-2018)
Table 8. Karyopharm Therapeutics SWOT Analysis
Table 9. Karyopharm Therapeutics Hematological Cancers Product and Solutions
Table 10. Karyopharm Therapeutics Hematological Cancers Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Abbott Laboratories Corporate Information, Location and Competitors
Table 12. Abbott Laboratories Hematological Cancers Major Business
Table 13. Abbott Laboratories Hematological Cancers Total Revenue (USD Million) (2018-2019)
Table 14. Abbott Laboratories SWOT Analysis
Table 15. Abbott Laboratories Hematological Cancers Product and Solutions
Table 16. Abbott Laboratories Hematological Cancers Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. AbbVie Corporate Information, Location and Competitors
Table 18. AbbVie Hematological Cancers Major Business
Table 19. AbbVie Hematological Cancers Total Revenue (USD Million) (2017-2018)
Table 20. AbbVie SWOT Analysis
Table 21. AbbVie Hematological Cancers Product and Solutions
Table 22. AbbVie Hematological Cancers Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Johnson & Johnson Corporate Information, Location and Competitors
Table 24. Johnson & Johnson Hematological Cancers Major Business
Table 25. Johnson & Johnson Hematological Cancers Total Revenue (USD Million) (2017-2018)
Table 26. Johnson & Johnson SWOT Analysis
Table 27. Johnson & Johnson Hematological Cancers Product and Solutions
Table 28. Johnson & Johnson Hematological Cancers Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Celgene Corporation Corporate Information, Location and Competitors
Table 30. Celgene Corporation Hematological Cancers Major Business
Table 31. Celgene Corporation Hematological Cancers Total Revenue (USD Million) (2017-2018)
Table 32. Celgene Corporation SWOT Analysis
Table 33. Celgene Corporation Hematological Cancers Product and Solutions
Table 34. Celgene Corporation Hematological Cancers Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Roche Diagnostics A/S Corporate Information, Location and Competitors
Table 36. Roche Diagnostics A/S Hematological Cancers Major Business
Table 37. Roche Diagnostics A/S Hematological Cancers Total Revenue (USD Million) (2017-2018)
Table 38. Roche Diagnostics A/S SWOT Analysis
Table 39. Roche Diagnostics A/S Hematological Cancers Product and Solutions
Table 40. Roche Diagnostics A/S Hematological Cancers Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. HemoCue AB Corporate Information, Location and Competitors
Table 42. HemoCue AB Hematological Cancers Major Business
Table 43. HemoCue AB Hematological Cancers Total Revenue (USD Million) (2017-2018)
Table 44. HemoCue AB SWOT Analysis
Table 45. HemoCue AB Hematological Cancers Product and Solutions
Table 46. HemoCue AB Hematological Cancers Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. Kite Pharma Corporate Information, Location and Competitors
Table 48. Kite Pharma Hematological Cancers Major Business
Table 49. Kite Pharma Hematological Cancers Total Revenue (USD Million) (2017-2018)
Table 50. Kite Pharma SWOT Analysis
Table 51. Kite Pharma Hematological Cancers Product and Solutions
Table 52. Kite Pharma Hematological Cancers Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. Novartis Corporate Information, Location and Competitors
Table 54. Novartis Hematological Cancers Major Business
Table 55. Novartis Hematological Cancers Total Revenue (USD Million) (2017-2018)
Table 56. Novartis SWOT Analysis
Table 57. Novartis Hematological Cancers Product and Solutions
Table 58. Novartis Hematological Cancers Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 59. Beckman Coulter Corporate Information, Location and Competitors
Table 60. Beckman Coulter Hematological Cancers Major Business
Table 61. Beckman Coulter Hematological Cancers Total Revenue (USD Million) (2017-2018)
Table 62. Beckman Coulter SWOT Analysis
Table 63. Beckman Coulter Hematological Cancers Product and Solutions
Table 64. Beckman Coulter Hematological Cancers Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 65. Bio-Rad Laboratories Corporate Information, Location and Competitors
Table 66. Bio-Rad Laboratories Hematological Cancers Major Business
Table 67. Bio-Rad Laboratories Hematological Cancers Total Revenue (USD Million) (2017-2018)
Table 68. Bio-Rad Laboratories SWOT Analysis
Table 69. Bio-Rad Laboratories Hematological Cancers Product and Solutions
Table 70. Bio-Rad Laboratories Hematological Cancers Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 71. Horiba Corporate Information, Location and Competitors
Table 72. Horiba Hematological Cancers Major Business
Table 73. Horiba Hematological Cancers Total Revenue (USD Million) (2017-2018)
Table 74. Horiba SWOT Analysis
Table 75. Horiba Hematological Cancers Product and Solutions
Table 76. Horiba Hematological Cancers Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 77. C. R. Bard Corporate Information, Location and Competitors
Table 78. C. R. Bard Hematological Cancers Major Business
Table 79. C. R. Bard Hematological Cancers Total Revenue (USD Million) (2017-2018)
Table 80. C. R. Bard SWOT Analysis
Table 81. C. R. Bard Hematological Cancers Product and Solutions
Table 82. C. R. Bard Hematological Cancers Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 83. Astellas Pharma US Corporate Information, Location and Competitors
Table 84. Astellas Pharma US Hematological Cancers Major Business
Table 85. Astellas Pharma US Hematological Cancers Total Revenue (USD Million) (2017-2018)
Table 86. Astellas Pharma US SWOT Analysis
Table 87. Astellas Pharma US Hematological Cancers Product and Solutions
Table 88. Astellas Pharma US Hematological Cancers Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 89. The Medicine Company Corporate Information, Location and Competitors
Table 90. The Medicine Company Hematological Cancers Major Business
Table 91. The Medicine Company Hematological Cancers Total Revenue (USD Million) (2017-2018)
Table 92. The Medicine Company SWOT Analysis
Table 93. The Medicine Company Hematological Cancers Product and Solutions
Table 94. The Medicine Company Hematological Cancers Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 95. Mindray Medical International Limited Corporate Information, Location and Competitors
Table 96. Mindray Medical International Limited Hematological Cancers Major Business
Table 97. Mindray Medical International Limited Hematological Cancers Total Revenue (USD Million) (2017-2018)
Table 98. Mindray Medical International Limited SWOT Analysis
Table 99. Mindray Medical International Limited Hematological Cancers Product and Solutions
Table 100. Mindray Medical International Limited Hematological Cancers Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 101. Siemens AG Corporate Information, Location and Competitors
Table 102. Siemens AG Hematological Cancers Major Business
Table 103. Siemens AG Hematological Cancers Total Revenue (USD Million) (2017-2018)
Table 104. Siemens AG SWOT Analysis
Table 105. Siemens AG Hematological Cancers Product and Solutions
Table 106. Siemens AG Hematological Cancers Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 107. DiagnoCure Inc. Hematological Cancers Type and Application
Table 108. DiagnoCure Inc. Hematological Cancers Major Business
Table 109. DiagnoCure Inc. Hematological Cancers Total Revenue (USD Million) (2017-2018)
Table 110. DiagnoCure Inc. SWOT Analysis
Table 111. DiagnoCure Inc. Hematological Cancers Product and Solutions
Table 112. DiagnoCure Inc. Hematological Cancers Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 113. Pharmacyclics Corporate Information, Location and Competitors
Table 114. Pharmacyclics Hematological Cancers Major Business
Table 115. Pharmacyclics Hematological Cancers Total Revenue (USD Million) (2017-2018)
Table 116. Pharmacyclics SWOT Analysis
Table 117. Pharmacyclics Hematological Cancers Product and Solutions
Table 118. Pharmacyclics Hematological Cancers Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 119. Sysmex Corporate Information, Location and Competitors
Table 120. Sysmex Hematological Cancers Major Business
Table 121. Sysmex Hematological Cancers Total Revenue (USD Million) (2017-2018)
Table 122. Sysmex SWOT Analysis
Table 123. Sysmex Hematological Cancers Product and Solutions
Table 124. Sysmex Hematological Cancers Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 125. Global Hematological Cancers Revenue (Million USD) by Players (2015-2020)
Table 126. Global Hematological Cancers Revenue Share by Players (2015-2020)
Table 127. Global Hematological Cancers Revenue (Million USD) by Regions (2015-2020)
Table 128. Global Hematological Cancers Revenue Market Share by Regions (2015-2020)
Table 129. North America Hematological Cancers Revenue by Countries (2015-2020)
Table 130. North America Hematological Cancers Revenue Market Share by Countries (2015-2020)
Table 131. Europe Hematological Cancers Revenue (Million USD) by Countries (2015-2020)
Table 132. Asia-Pacific Hematological Cancers Revenue (Million USD) by Countries (2015-2020)
Table 133. South America Hematological Cancers Revenue by Countries (2015-2020)
Table 134. South America Hematological Cancers Revenue Market Share by Countries (2015-2020)
Table 135. Middle East and Africa Hematological Cancers Revenue (Million USD) by Countries (2015-2020)
Table 136. Middle East and Africa Hematological Cancers Revenue Market Share by Countries (2015-2020)
Table 137. Global Hematological Cancers Revenue (Million USD) by Type (2015-2020)
Table 138. Global Hematological Cancers Revenue Share by Type (2015-2020)
Table 139. Global Hematological Cancers Revenue Forecast by Type (2021-2025)
Table 140. Global Hematological Cancers Revenue by Application (2015-2020)
Table 141. Global Hematological Cancers Revenue Share by Application (2015-2020)
Table 142. Global Hematological Cancers Revenue Forecast by Application (2021-2025)
Table 143. Global Hematological Cancers Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Hematological Cancers Picture
Figure 2. Global Hematological Cancers Revenue Market Share by Type in 2019
Figure 3. Pharmacological Therapies Picture
Figure 4. Stem Cell Transplantation Picture
Figure 5. Surgery and Radiation Therapy Picture
Figure 6. Anemia Treatment Picture
Figure 7. Thrombosis Treatment Picture
Figure 8. Neutopenia Treatment Picture
Figure 9. Symptomatic treatment Picture
Figure 10. Hematological Cancers Revenue Market Share by Application in 2019
Figure 11. Epidemiology Picture
Figure 12. Pathophysiology of Leukemic Stem Cells Picture
Figure 13. Kidney Diseases Picture
Figure 14. Genetic Diseases Picture
Figure 15. Other Diseases Picture
Figure 16. Global Hematological Cancers Revenue (USD Million) and Growth Rate (2015-2025)
Figure 17. North America Hematological Cancers Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. Europe Hematological Cancers Revenue (Million USD) and Growth Rate (2015-2025)
Figure 19. Asia-Pacific Hematological Cancers Revenue (Million USD) and Growth Rate (2015-2025)
Figure 20. South America Hematological Cancers Revenue (Million USD) and Growth Rate (2015-2025)
Figure 21. Middle East and Africa Hematological Cancers Revenue (Million USD) and Growth Rate (2015-2025)
Figure 22. Global Hematological Cancers Revenue (Million USD) and Growth Rate (2015-2025)
Figure 23. Global Hematological Cancers Revenue Share by Players in 2019
Figure 24. Global Top 5 Players Hematological Cancers Revenue Market Share in 2019
Figure 25. Global Top 10 Players Hematological Cancers Revenue Market Share in 2019
Figure 26. Key Players Market Share Trend
Figure 27. Global Hematological Cancers Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 28. Global Hematological Cancers Revenue Market Share by Regions (2015-2020)
Figure 29. Global Hematological Cancers Revenue Market Share by Regions in 2018
Figure 30. North America Hematological Cancers Revenue and Growth Rate (2015-2020)
Figure 31. Europe Hematological Cancers Revenue and Growth Rate (2015-2020)
Figure 32. Asia-Pacific Hematological Cancers Revenue and Growth Rate (2015-2020)
Figure 33. South America Hematological Cancers Revenue and Growth Rate (2015-2020)
Figure 34. Middle East and Africa Hematological Cancers Revenue and Growth Rate (2015-2020)
Figure 35. North America Hematological Cancers Revenue Market Share by Countries (2015-2020)
Figure 36. North America Hematological Cancers Revenue Market Share by Countries in 2019
Figure 37. USA Hematological Cancers Revenue and Growth Rate (2015-2020)
Figure 38. Canada Hematological Cancers Revenue and Growth Rate (2015-2020)
Figure 39. Mexico Hematological Cancers Revenue and Growth Rate (2015-2020)
Figure 40. Europe Hematological Cancers Revenue Market Share by Countries (2015-2020)
Figure 41. Europe Hematological Cancers Revenue Market Share by Countries in 2019
Figure 42. Germany Hematological Cancers Revenue and Growth Rate (2015-2020)
Figure 43. UK Hematological Cancers Revenue and Growth Rate (2015-2020)
Figure 44. France Hematological Cancers Revenue and Growth Rate (2015-2020)
Figure 45. Russia Hematological Cancers Revenue and Growth Rate (2015-2020)
Figure 46. Italy Hematological Cancers Revenue and Growth Rate (2015-2020)
Figure 47. Asia-Pacific Hematological Cancers Revenue Market Share by Countries (2015-2020)
Figure 48. Asia-Pacific Hematological Cancers Revenue Market Share by Countries in 2019
Figure 49. China Hematological Cancers Revenue and Growth Rate (2015-2020)
Figure 50. Japan Hematological Cancers Revenue and Growth Rate (2015-2020)
Figure 51. Korea Hematological Cancers Revenue and Growth Rate (2015-2020)
Figure 52. India Hematological Cancers Revenue and Growth Rate (2015-2020)
Figure 53. Southeast Asia Hematological Cancers Revenue and Growth Rate (2015-2020)
Figure 54. South America Hematological Cancers Revenue Market Share by Countries (2015-2020)
Figure 55. South America Hematological Cancers Revenue Market Share by Countries in 2019
Figure 56. Brazil Hematological Cancers Revenue and Growth Rate (2015-2020)
Figure 57. Argentina Hematological Cancers Revenue and Growth Rate (2015-2020)
Figure 58. Middle East and Africa Hematological Cancers Revenue Market Share by Countries (2015-2020)
Figure 59. Middle East and Africa Hematological Cancers Revenue Market Share by Countries in 2019
Figure 60. Saudi Arabia Hematological Cancers Revenue and Growth Rate (2015-2020)
Figure 61. UAE Hematological Cancers Revenue and Growth Rate (2015-2020)
Figure 62. Egypt Hematological Cancers Revenue and Growth Rate (2015-2020)
Figure 63. South Africa Hematological Cancers Revenue and Growth Rate (2015-2020)
Figure 64. Global Hematological Cancers Revenue Share by Type (2015-2020)
Figure 65. Global Hematological Cancers Revenue Share by Type in 2019
Figure 66. Global Hematological Cancers Market Share Forecast by Type (2021-2025)
Figure 67. Global Pharmacological Therapies Revenue Growth Rate (2015-2020)
Figure 68. Global Stem Cell Transplantation Revenue Growth Rate (2015-2020)
Figure 69. Global Surgery and Radiation Therapy Revenue Growth Rate (2015-2020)
Figure 70. Global Anemia Treatment Revenue Growth Rate (2015-2020)
Figure 71. Global Thrombosis Treatment Revenue Growth Rate (2015-2020)
Figure 72. Global Neutopenia Treatment Revenue Growth Rate (2015-2020)
Figure 73. Global Symptomatic treatment Revenue Growth Rate (2015-2020)
Figure 74. Global Hematological Cancers Revenue Share by Application (2015-2020)
Figure 75. Global Hematological Cancers Revenue Share by Application in 2019
Figure 76. Global Hematological Cancers Market Share Forecast by Application (2021-2025)
Figure 77. Global Epidemiology Revenue Growth Rate (2015-2020)
Figure 78. Global Pathophysiology of Leukemic Stem Cells Revenue Growth Rate (2015-2020)
Figure 79. Global Kidney Diseases Revenue Growth Rate (2015-2020)
Figure 80. Global Genetic Diseases Revenue Growth Rate (2015-2020)
Figure 81. Global Other Diseases Revenue Growth Rate (2015-2020)
Figure 82. Global Hematological Cancers Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 83. Global Hematological Cancers Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 84. Global Hematological Cancers Revenue Market Share Forecast by Regions (2021-2025)
Figure 85. North America Hematological Cancers Revenue Market Forecast (2021-2025)
Figure 86. Europe Hematological Cancers Revenue Market Forecast (2021-2025)
Figure 87. Asia-Pacific Hematological Cancers Revenue Market Forecast (2021-2025)
Figure 88. South America Hematological Cancers Revenue Market Forecast (2021-2025)
Figure 89. Middle East and Africa Hematological Cancers Revenue Market Forecast (2021-2025)
Figure 90. Sales Channel: Direct Channel vs Indirect Channel
血液疾患薬＆診断の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Drugs and Diagnostics for Hematological Disorders market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 4.1% in the forecast period of 2020 to 2025 and will expected to reach USD 114160 million by 2025, from USD 97320 million …- 細胞診の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Cytology Examination market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Cytology Examination mar…
- 粒子処理装置の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Particle Treatment Devices market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Particle Treatment…
- 若年性黄斑変性症（シュタルガルト病）治療の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Juvenile Macular Degeneration (Stargardt Disease) Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx millio…
- 消化管間質腫瘍（GIST）治療の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Gastrointestinal Stromal Tumors (GISTs) Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.…